These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 33305541)

  • 1. Comparison of Lesional Juvenile Myositis and Lupus Skin Reveals Overlapping Yet Unique Disease Pathophysiology.
    Turnier JL; Pachman LM; Lowe L; Tsoi LC; Elhaj S; Menon R; Amoruso MC; Morgan GA; Gudjonsson JE; Berthier CC; Kahlenberg JM
    Arthritis Rheumatol; 2021 Jun; 73(6):1062-1072. PubMed ID: 33305541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin.
    Lambers WM; de Leeuw K; Doornbos-van der Meer B; Diercks GFH; Bootsma H; Westra J
    Arthritis Res Ther; 2019 Dec; 21(1):260. PubMed ID: 31791398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.
    Kim H; Gunter-Rahman F; McGrath JA; Lee E; de Jesus AA; Targoff IN; Huang Y; O'Hanlon TP; Tsai WL; Gadina M; Miller FW; Goldbach-Mansky R; Rider LG
    Arthritis Res Ther; 2020 Apr; 22(1):69. PubMed ID: 32252809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures.
    Brohawn PZ; Streicher K; Higgs BW; Morehouse C; Liu H; Illei G; Ranade K
    Lupus; 2019 Nov; 28(13):1524-1533. PubMed ID: 31660791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis.
    Lu X; Tang Q; Lindh M; Dastmalchi M; Alexanderson H; Popovic Silwerfeldt K; Agerberth B; Lundberg IE; Wick C
    J Autoimmun; 2017 Mar; 78():46-56. PubMed ID: 28012697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic lupus erythematosus overlapping dermatomyositis owing to a heterozygous TREX1 Asp130Asn missense mutation.
    Endo Y; Koga T; Otaki H; Furukawa K; Kawakami A
    Clin Immunol; 2021 Jun; 227():108732. PubMed ID: 33892200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis.
    Soponkanaporn S; Deakin CT; Schutz PW; Marshall LR; Yasin SA; Johnson CM; Sag E; Tansley SL; McHugh NJ; Wedderburn LR; Jacques TS
    Neuropathol Appl Neurobiol; 2019 Jun; 45(4):410-420. PubMed ID: 29770465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells.
    Shrestha S; Wershil B; Sarwark JF; Niewold TB; Philipp T; Pachman LM
    Arthritis Rheum; 2010 Sep; 62(9):2813-22. PubMed ID: 20506305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IRF4 and IRGs Delineate Clinically Relevant Gene Expression Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis.
    Rodríguez-Carrio J; López P; Alperi-López M; Caminal-Montero L; Ballina-García FJ; Suárez A
    Front Immunol; 2018; 9():3085. PubMed ID: 30666255
    [No Abstract]   [Full Text] [Related]  

  • 10. From Diagnosis to Prognosis: Revisiting the Meaning of Muscle ISG15 Overexpression in Juvenile Inflammatory Myopathies.
    Hou C; Durrleman C; Periou B; Barnerias C; Bodemer C; Desguerre I; Quartier P; Melki I; Rice GI; Rodero MP; Charuel JL; Relaix F; Bader-Meunier B; Authier F; Gitiaux C
    Arthritis Rheumatol; 2021 Jun; 73(6):1044-1052. PubMed ID: 33314705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies.
    Hua J; Kirou K; Lee C; Crow MK
    Arthritis Rheum; 2006 Jun; 54(6):1906-16. PubMed ID: 16736505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity.
    Liu M; Liu J; Hao S; Wu P; Zhang X; Xiao Y; Jiang G; Huang X
    Clin Rheumatol; 2018 Oct; 37(10):2675-2684. PubMed ID: 29774490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers.
    Chasset F; Ribi C; Trendelenburg M; Huynh-Do U; Roux-Lombard P; Courvoisier DS; Chizzolini C;
    Rheumatology (Oxford); 2020 Nov; 59(11):3468-3478. PubMed ID: 32375176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies.
    Ekholm L; Vosslamber S; Tjärnlund A; de Jong TD; Betteridge Z; McHugh N; Plestilova L; Klein M; Padyukov L; Voskuyl AE; Bultink IE; Michiel Pegtel D; Mavragani CP; Crow MK; Vencovsky J; Lundberg IE; Verweij CL
    Scand J Immunol; 2016 Aug; 84(2):100-9. PubMed ID: 27173897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets.
    Wenzel J; Zahn S; Mikus S; Wiechert A; Bieber T; Tüting T
    Br J Dermatol; 2007 Oct; 157(4):752-7. PubMed ID: 17714558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coordination of retrotransposons and type I interferon with distinct interferon pathways in dermatomyositis, systemic lupus erythematosus and autoimmune blistering disease.
    Kuriyama Y; Shimizu A; Kanai S; Oikawa D; Motegi SI; Tokunaga F; Ishikawa O
    Sci Rep; 2021 Nov; 11(1):23146. PubMed ID: 34848794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA-seq Analysis Reveals Unique Transcriptome Signatures in Systemic Lupus Erythematosus Patients with Distinct Autoantibody Specificities.
    Rai R; Chauhan SK; Singh VV; Rai M; Rai G
    PLoS One; 2016; 11(11):e0166312. PubMed ID: 27835693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus.
    Enocsson H; Wetterö J; Eloranta ML; Gullstrand B; Svanberg C; Larsson M; Bengtsson AA; Rönnblom L; Sjöwall C
    Front Immunol; 2021; 12():688753. PubMed ID: 34276678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioinformatics identification of key candidate genes and pathways associated with systemic lupus erythematosus.
    Yang F; Zhai Z; Luo X; Luo G; Zhuang L; Zhang Y; Li Y; Sun E; He Y
    Clin Rheumatol; 2020 Feb; 39(2):425-434. PubMed ID: 31673979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features.
    Moneta GM; Pires Marafon D; Marasco E; Rosina S; Verardo M; Fiorillo C; Minetti C; Bracci-Laudiero L; Ravelli A; De Benedetti F; Nicolai R
    Arthritis Rheumatol; 2019 Jun; 71(6):1011-1021. PubMed ID: 30552836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.